SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
IN PARTNERSHIP WITH TRILINK BIOTECHNOLOGIES
Webinar: Design, Build, and Encapsulate: Transforming Digital Sequences into High-Quality, Ready-to-Test mRNA
This webinar, tailored for scientists in academia, biotech, and pharma, explores how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.
October 15, 2025
 · 
1 min read
 · 
BioSpace Insights
Facade of Novo Nordisk's office in Fremont, California
Rare diseases
Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work
Novo Nordisk strikes another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work.
October 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Check mate. hand of businessman moving chess figure Trendy 3d collage in magazine style. Contemporary art. Modern design
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
October 15, 2025
 · 
2 min read
 · 
Annalee Armstrong
Group of paper boat in one direction and with one individual pointing in the different way. Business for innovative solution concept.3D rendering on blue background.
Gene therapy
Sarepta’s Not Done With Gene Therapy Yet as LGMD Asset Yields Promising Data
Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain.
October 15, 2025
 · 
6 min read
 · 
Tristan Manalac
Hair care treatment and repair, follicles with damaged structure and split ends, healthy on beige background 3d render icon set. Cosmetic product with keratin, shampoo mockup banner, 3D illustration
Funding
Pelage Pharmaceuticals Raises $120 Million To Grow Hair Loss Program
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth.
October 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Reaching an agreement. Businessmen shake hands and make a deal. vector
Collaboration
Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal
2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Bristol Myers Squibb office in California
ALS
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line
Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its option for an ALS target.
October 15, 2025
 · 
1 min read
 · 
Tristan Manalac
Creative poster collage of two business partners having deal financial payment giving money banknote isolated on beige color background.
Mergers & acquisitions
BioCryst Snaps Up Fellow Angiodema Player Astria for $700M
The acquisition will give BioCryst an investigational injectable drug for hereditary angioedema, potentially complementing its FDA-approved oral drug Orladeyo.
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major beneficiary” of this program, according to analysts at William Blair.
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS